New Name, Brand for Clinical Financial Services
Clinical Financial Services (CFS), a specialty provider focused on the business and financial management activities for clinical trials, announces its new name and brand image. The company will now be known as CFS Clinical. The new image and name reflects the company’s rapid and continued growth and highlights its expanded service offerings.
CFS Clinical has two service areas within clinical trial business management: Contract and Regulatory Services and Global Payment Services which operate in unison to accelerate cycle times, manage compliance and risk and stimulate investigator relationships. To support these services, CFS Clinical has reinvented and revolutionized its technology platforms — CFS Startup InSite™ and CFS Payment InSite™ — both of which were unveiled at the DIA Conference.
According to Greg Seminack, President and Managing Partner of CFS Clinical, “Our new brand image captures what CFS Clinical is known for — transforming the business of clinical trials. It reinforces the fact that our ultimate goal is to empower biopharmaceutical and medical device companies worldwide to initiate and complete clinical trials quickly and efficiently, with better metrics and measurable ROI.” Mr. Seminack continues, “We are pleased to unveil our new identity and the continued investment in new service offerings that our new name conveys.”
Using Patient Reported Outcomes in Dermatology Trials
April 25th 2024In part 3 of this video interview with ACT editor Andy Studna, Melissa Mooney, director, eCOA sales engineering, IQVIA sheds light on the unique challenges of dermatology trials and how clinical outcome assessments can be implemented in them.
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Improving Engagement While Maintaining Data Integrity & Validity
March 19th 2024In recognition of Women's Health Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and uMotif's Chief Product Officer, Julia Lakeland, discuss new technologies improving patient engagement and reducing the emotional and logistical burdens of participation, ethical considerations that should be addressed when implementing those technologies, while ensuring patient privacy, and much more.
FDA Grants Ziftomenib with Breakthrough Therapy Designation for NPM1-Mutant Acute Myeloid Leukemia
April 23rd 2024Data from the Phase Ib portion of the KOMET-001 trial showed that the once-daily oral treatment may provide a substantial improvement over available therapies for relapsed/refractory NPM1-mutant acute myeloid leukemia.
